IBDEI1EG ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,25096,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25096,1,4,0)
 ;;=4^451.9
 ;;^UTILITY(U,$J,358.3,25096,1,5,0)
 ;;=5^Thrombophlebitis 
 ;;^UTILITY(U,$J,358.3,25096,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,25097,0)
 ;;=446.6^^145^1535^122
 ;;^UTILITY(U,$J,358.3,25097,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25097,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,25097,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpura(Ttp)
 ;;^UTILITY(U,$J,358.3,25097,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,25098,0)
 ;;=286.4^^145^1535^125
 ;;^UTILITY(U,$J,358.3,25098,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25098,1,4,0)
 ;;=4^286.4
 ;;^UTILITY(U,$J,358.3,25098,1,5,0)
 ;;=5^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,25098,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,25099,0)
 ;;=204.00^^145^1535^1
 ;;^UTILITY(U,$J,358.3,25099,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25099,1,4,0)
 ;;=4^204.00
 ;;^UTILITY(U,$J,358.3,25099,1,5,0)
 ;;=5^ALL w/o Remission
 ;;^UTILITY(U,$J,358.3,25099,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,25100,0)
 ;;=204.01^^145^1535^3
 ;;^UTILITY(U,$J,358.3,25100,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25100,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,25100,1,5,0)
 ;;=5^ALL,In Remission
 ;;^UTILITY(U,$J,358.3,25100,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,25101,0)
 ;;=204.10^^145^1535^16
 ;;^UTILITY(U,$J,358.3,25101,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25101,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,25101,1,5,0)
 ;;=5^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,25101,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,25102,0)
 ;;=204.11^^145^1535^18
 ;;^UTILITY(U,$J,358.3,25102,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25102,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,25102,1,5,0)
 ;;=5^CLL,In Remission
 ;;^UTILITY(U,$J,358.3,25102,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,25103,0)
 ;;=201.90^^145^1535^83
 ;;^UTILITY(U,$J,358.3,25103,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25103,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,25103,1,5,0)
 ;;=5^Hodgkin's Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,25103,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,25104,0)
 ;;=785.6^^145^1535^89
 ;;^UTILITY(U,$J,358.3,25104,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25104,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,25104,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,25104,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,25105,0)
 ;;=200.20^^145^1535^90
 ;;^UTILITY(U,$J,358.3,25105,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25105,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,25105,1,5,0)
 ;;=5^Lymphoma,Burkitt's,Site Unspec
 ;;^UTILITY(U,$J,358.3,25105,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,25106,0)
 ;;=202.00^^145^1535^92
 ;;^UTILITY(U,$J,358.3,25106,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25106,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,25106,1,5,0)
 ;;=5^Lymphoma,Low-Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,25106,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,25107,0)
 ;;=200.10^^145^1535^91
 ;;^UTILITY(U,$J,358.3,25107,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25107,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,25107,1,5,0)
 ;;=5^Lymphoma,Int or High Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,25107,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,25108,0)
 ;;=273.3^^145^1535^93
 ;;^UTILITY(U,$J,358.3,25108,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25108,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,25108,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,25108,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,25109,0)
 ;;=203.00^^145^1535^103
 ;;^UTILITY(U,$J,358.3,25109,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25109,1,4,0)
 ;;=4^203.00
